Evidence map›Paper›PMID 38928706›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Gabriele Masselli, Saadi Sollaku, Cristina De Angelis, Elisabetta Polettini, Gianfranco Gualdi, Emanuele Casciani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriele MasselliDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, "Sapienza" University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy.
Saadi SollakuPET/CT Section, Pio XI Private Hospital, Via Aurelia 559, 00165 Rome, Italy.
Cristina De AngelisPET/CT Section, Pio XI Private Hospital, Via Aurelia 559, 00165 Rome, Italy.ORCID 0000-0003-0638-3463
Elisabetta PolettiniPET/CT Section, Pio XI Private Hospital, Via Aurelia 559, 00165 Rome, Italy.
Gianfranco GualdiPET/CT Section, Pio XI Private Hospital, Via Aurelia 559, 00165 Rome, Italy.
Emanuele CascianiPET/CT Section, Pio XI Private Hospital, Via Aurelia 559, 00165 Rome, Italy.ORCID 0000-0001-6216-8923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsA total of 128 patients scanned with

resultsAccording to PSMA-RADS v2.0, we classified patients as follows: 23 patients without PSMA-RADS because they were negative; PSMA-RADS 1: 10 patients; PSMA-RADS 2: 4 patients; PSMA-RADS 3A: 11 patients; PSMA-RADS 3B: 2 patients; PSMA-RADS 3C: 2 patients; PSMA-RADS 3D: 2 patients; PSMA-RADS 4: 13 patients; PSMA-RADS 5: 61 patients.

conclusionsThe overall detection rate of

conclusionUsing PSMA-RADS version 2.0, we obtained detection rate values comparable with recent literature both in absolute terms and in relation to different PSA levels.

Indexed as

68Ga-PSMA68Ga-PSMA PET/CTbiochemical recurrenceprostate cancerPSMA-RADS

Identifiers

PMID38928706
PMCPMC11202891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.